Patient Engagement Specialist
The specialist will support the company's commitment to building strong relationships with patients, caregivers and patient advocacy communities. This position will report to the Manager of Patient Engagement. The qualified candidate will be responsible for identifying and supporting relationships with national and patient groups for the company's inflammatory and fibrotic disease portfolio; and support the company's philanthropic fundraising efforts.
Support the Patient Engagement team's efforts to work with patient organizations and individual patient advocates
Manage all company philanthropic fundraising efforts, which includes organizing external/internal fundraising events, creating a vendor sponsorship program and motivating employees
Coordinate the company's presence at national and local patient advocacy events (conferences, walks, runs and local events)
Manage the execution of monthly sponsorship committee meeting, including creating an agenda, taking minutes, maintaining budget and updating grant application
Develop and oversee maintenance of a relationship tracking database
Coordinate of patient presentations for internal meetings
Evaluate the competitive landscape to ensure the company's initiatives align with others in the industry
Develop background and bio documents
Conduct patient advocacy landscape assessment focused of new disease areas of interest, identify strategic partnerships to support the company and patient community on the local level
Keep up-to-date with current with relevant information and resources regarding industry and healthcare legislation
Track metrics, analytics and performance reporting methods to measure impact
Bachelor's degree in communications, patient advocacy, or a related field
Minimum two years of experience in patient advocacy, communications or a related field
Flexibility working under tight deadlines and ability to effectively plan, prioritize, execute, budget, follow up and anticipate challenges
Good listening skills, demonstrated empathy, a conscientious team player with the ability to maintain composure in stressful situations
Ability to work cross-functionally and build strategic alliances internally and externally
Business travel required
Corbus is a close-knit team of almost 100 employees who are high-achievers, innovative, creative and, above all else, passionate about what we do. We hire for personality as well as for skill.
You must thrive in an entrepreneurial and autonomous environment where you will succeed based on your contribution and work ethic, not on your title or rank. At Corbus we take pride in our "family" atmosphere where each person's contribution is vital to our success. As a Corbus employee, you are empowered to think creatively and be proactive in your approach. There is no place for politics or red tape here. Positive, team-oriented people work at Corbus and are rewarded with fun perks like weekly food deliveries to our kitchen, a monthly in-house massage therapist, company-paid classes with Title Boxing, and organized company activities and outings. Additionally, Corbus offers an attractive, comprehensive benefits package.
Corbus Pharmaceuticals Holdings, Inc. (NASDQ: CRBP) is a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat inflammatory and fibrotic diseases by leveraging its industry leading pipeline of endocannabinoid system-targeting drug candidates. The Company's lead product candidate, Lenabasum, is a novel, synthetic, oral, selective cannabinoid receptor type 2 (CB2) agonist designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus.
Corbus licensed the exclusive worldwide rights to develop, manufacture and market drug candidates from more than 600 novel compounds targeting the endocannabinoid system from Jenrin Discovery LLC. The pipeline includes CRB-4001, a 2nd generation, peripherally-restricted, selective cannabinoid receptor type 1 (CB1) inverse agonist specifically designed to eliminate blood-brain barrier penetration and brain CB1 receptor occupancy that mediate the neuropsychiatric issues associated with first-generation CB1 inverse agonists. Potential indications for CRB-4001 include NASH, primary biliary cholangitis, idiopathic pulmonary fibrosis, radiation-induced pulmonary fibrosis, myocardial fibrosis after myocardial infarction and acute interstitial nephritis, among others. CRB-4001 is scheduled to enter a Phase 1 study in 2019 followed a National Institutes of Health (NIH)-funded first-in-patient Phase 2 study.
Corbus Pharmaceuticals Holdings, Inc. is an equal opportunity employer
Corbus Pharmaceuticals Holdings, Inc.